[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"eczema-atopic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:eczema-atopic":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,71,95,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100637567","phase-2-a-phase-2b-study-of-the-effects-of-camoteskimab-in-adults-with-moderate-to-severe-atopic-dermatitis-100637567",false,"NCT07599813","A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis","A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n1. Age 18-65 inclusive, at the time of signing the informed consent.\n2. Chronic AD for at least 1 year based on clinically confirmed diagnosis of active AD, according to Hanfin and Rajka criteria.\n3. Participants with moderate-to-severe AD defined by:\n\n   1. Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Screening and Baseline.\n   2. AD involvement of ≥ 10% body surface area (BSA) at Screening and Baseline.\n   3. EASI score of ≥ 16 at Screening and at Baseline.\n   4. Peak pruritus numerical rating scale (PP-NRS) ≥ 4 at Baseline. Note: The PP-NRS will be calculated from the 7 consecutive days immediately preceding Baseline. A minimum of 4 daily scores out of the 7 days is needed.\n4. Participants who are candidates for systemic therapy, defined as history of inadequate response to topical AD treatments applied for at least 28 days, or for the maximum duration recommended by the product prescribing information, or for treatment with topical AD treatments is medically inadvisable due to important side effects or safety risks.\n5. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n6. Participant provides signed informed consent\n\nExclusion Criteria:\n\n1. History or other evidence of severe illness or any other conditions such as psychiatric illness, severe depression or previous history of suicidal attempt in past 10 years that would render the participant, in the opinion of the Investigator, unsuitable for the study.\n2. Active, chronic or acute infection requiring systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the Baseline.\n3. Participant has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of AD or would interfere with the study assessments based on the Investigator's judgement.\n4. Participant has history of significant flares of AD within 4 weeks prior to screening, in the opinion of the investigator.\n5. Participant has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma) based on investigator judgement.\n6. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting electrocardiogram (ECG) and any clinically significant abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of QTc interval changes.\n7. Participant has severe and uncontrolled seasonal or allergic rhinitis, severe and uncontrolled asthma or any other severe and uncontrolled atopic disease as judged by the Investigator.\n8. Treatment of AD with medicated moisturizers available only by prescription within 2 weeks prior to the Baseline visit.\n9. Active human immunodeficiency virus (HIV): confirmed positive anti-HIV antibody (HIV Ab) test.\n10. Active hepatitis B virus (HBV): hepatitis B surface antigen (HBs Ag) positive (+) or hepatitis B core antibody (HBc Ab) positive (+) confirmed by HBV PCR positive (+).\n11. Active hepatitis C virus (HCV): If hepatitis C antibody positive (+), confirmed by HCV RNA test. Note: a participant with documented proof of cure from HCV may be enrolled.\n12. Evidence of active or latent tuberculosis.\n13. Receipt of live or attenuated live vaccine within 6 weeks prior to screening.\n14. Participant had a major surgery within 8 weeks prior to Baseline or has a major surgery planned during the study.\n15. Participant is known to have immune deficiency or is immunocompromised\n16. Diagnosed with a malignancy within 5 years of enrollment (suspected malignancy should be ruled out by blood or tissue biopsy, as applicable) with the exception of:\n\n    * Completely resected basal cell or squamous cell carcinoma of the skin.\n    * Carcinoma in situ of the cervix.\n17. Has had previous exposure to anti-IL-18 therapy.\n18. Known allergy\u002Fsensitivity to any component of IMP.\n19. History of use of any of these medications as follows:\n\n    1. Dupilumab, tralokinumab, lebrikizumab, nemolizumab within 8 weeks prior to Baseline.\n    2. Systemic JAKi within 4 weeks prior to Baseline.\n    3. Any topical medicated treatment that could affect AD within 2 weeks prior to Baseline, including, but not limited to, topical corticosteroids, topical phosphodiesterase (PDE4) inhibitors, topical calcineurin inhibitors, topical JAKi, tars, antimicrobials, medical devices, and bleach baths.\n    4. Systemic therapies (other than biologics) that could affect AD not noted above, within 4 weeks prior to Baseline, including but not limited to, retinoids, calcineurin inhibitors, methotrexate, hydroxycarbamide (hydroxyurea), azathioprine, oral\u002Finjectable corticosteroids. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.\n    5. Treatment with any investigational biologic agent or biologic agent approved after publication of this protocol, within 12 weeks (or 5 half-lives, whichever is greater) of screening.\n    6. Treatment with any investigational nonbiologic agent, or any investigational device or procedure, within 4 weeks (or 5 half-lives, whichever is greater) of screening.\n    7. UV-B phototherapy (including tanning beds) or excimer laser use within 4 weeks prior to Baseline or during the study.\n    8. PUVA treatment within 4 weeks prior to Baseline\n    9. Sedating antihistamines, including but not limited to doxepin, hydroxyzine or diphenhydramine within 1 week prior to Baseline\n    10. Topical products containing urea within 1 week prior to Baseline\n    11. Systemic antibiotics within 2 weeks or topical antibiotics within 1 week prior to Baseline\n    12. Intravenous immunoglobulin (IVIg) therapy within 12 weeks prior to Baseline.\n20. Female participant who is pregnant or breastfeeding or trying to conceive.\n21. Participant considered unlikely to adhere to treatment and\u002For follow the protocol in the opinion of the Investigator.","ALL","18 Years","65 Years",{"count":20,"type":21},280,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.",[27,28,29,30,31,32,33,34],"Atopic Dermatitis","Atopic","Dermatitis","Dermatitis, Atopic","Dermatologic Disease","Eczema","Eczema Atopic Dermatitis","Eczema, Atopic","RECRUITING","2026-05-29",{"date":38,"type":39},"2026-06-02","ACTUAL",{"date":41,"type":39},"2026-05-28",{"date":43,"type":21},"2028-04-30",{"name":45,"class":46},"Apollo Therapeutics Ltd","INDUSTRY",85,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100609549","phase-2-a-study-to-learn-about-study-medicine-called-pf-08049820-in-people-with-eczema-100609549","NCT07216027","A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema","A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","Inclusion Criteria:\n\nParticipants must meet the following criteria:\n\n1. Are 18 years of age or older\n2. Have clinical diagnosis of AD for at least 6 months prior to Day 1 and have diagnosis of AD confirmed by photographs\n3. Have moderate to severe AD as defined by the following at screening and baseline visits:\n\n   * Affected body surface area (BSA) greater than or equal to 10% and up to 60%;\n   * Validated Investigator's Global Assessment (vIGA) greater than or equal to 3;\n   * Eczema Area and Severity Index (EASI) greater than or equal to 16;\n\n   AND\n\n   -Peak Pruritis Numeric Rating Scale (PP-NRS) greater than or equal to 4 at screening and a weekly average of greater than or equal to 4 at baseline visit\n4. Do not have a suitable prescribed medicine for AD.\n5. Body Mass Index (BMI) of 17.5 to 40 kg\u002Fm2 and a total body weight greater than 45 kg (100 lbs)\n\nExclusion Criteria:\n\nParticipants must not meet the following criteria:\n\n1. Have an infection that requires treatment\n2. Have other skin conditions other than AD\n3. Have severe uncontrolled asthma\n4. Regular use (more than 2 visits per week) of a tanning booth or phototherapy for AD within 4 weeks of the screening visit",{"count":56,"type":21},165,[24],"The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin.\n\nThe study is seeking participants who:\n\n1. Are aged 18 years or older;\n2. Were confirmed to have AD at least 6 months ago;\n3. Do not have a suitable prescribed medicine for AD;\n4. Are considered by their doctors to have moderate to severe AD.\n\nThe study has two stages (Stage 1 and Stage 2). In both stages, eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12. They will have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. They will have blood and urine tests. They will also have to answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to those receiving placebo. This will help to understand if PF-08049820 is safe and effective.",[27,34],[32,27],"2026-05-22",{"date":63,"type":39},"2026-05-27",{"date":65,"type":39},"2025-11-20",{"date":67,"type":21},"2028-02-02",{"name":69,"class":46},"Pfizer",10,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100626881","phase-2-study-to-evaluate-soquelitinib-in-participants-with-moderate-to-severe-ad-100626881","NCT07441395","Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD","A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)","SIERRA1","Inclusion Criteria:\n\n* Adult male or female, ≥18 years of age, as applicable according to local legislation, at Screening.\n* Diagnosis of AD with onset of symptoms at least 1 year prior to the Screening visit.\n* Moderate to severe disease at screening and pre-randomization on Day 1 defined by:\n* EASI ≥16\n* Body surface area ≥10%\n* vIGA ≥3\n* PP-NRS average score of ≥4 over a period of 7 days prior to randomization at Day 1.\n* Documented history of prior topical and\u002For systemic therapy for AD within 6 months of randomization.\n* A female participant is eligible if she is not pregnant or breastfeeding, and is either of non-childbearing potential, OR of childbearing potential and agrees to use highly effective birth control\n\nExclusion Criteria:\n\n* Other concomitant skin conditions that would interfere with evaluations of the effect of study medication on AD.\n* Other active skin diseases or skin infections (bacterial, fungal, or viral) requiring systemic treatment within 30 days of the Baseline visit or that could interfere with the appropriate assessment of AD lesions.\n* Known immunodeficiency syndrome, history of an invasive infection or active non skin-related infection requiring systemic anti-infective treatment within 30 days of Baseline.\n* History of immunosuppression not related to medication, history of clinically significant medical conditions, or any other reason which in the opinion of the investigator would interfere with the participant's participation in this study.\n* Have an unstable or uncontrolled illness, including but not limited to cerebrocardiovascular, respiratory, gastrointestinal, endocrine, hematologic, or neurologic disorders that would potentially affect participant safety within the study or confound efficacy and safety assessments.",{"count":80,"type":21},200,[24],"The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study.\n\nThe study doctors will see how safe soquelitinib is by tracking side effects among participants. They will also check \"tolerability,\" which means how well the participants can handle soquelitinib and whether any potential side effects are manageable for them.\n\nTo understand how well soquelitinib works, it will be compared with a placebo. Placebo is a substance that looks like soquelitinib but contains no active medicine in it.\n\nParticipants will:\n\n* Take study treatment (soquelitinib or placebo) every day for 12 weeks\n* Visit the clinic for check-ups and tests every week for the first 2 weeks then every 2 weeks during the treatment period, and then return for follow-up visits 30, 60, and 90 days after the last dose of study treatment",[27,84,32,34],"Atopic Dermatitis Eczema","2026-03-03",{"date":87,"type":39},"2026-03-05",{"date":89,"type":21},"2026-02",{"date":91,"type":21},"2027-09",{"name":93,"class":46},"Corvus Pharmaceuticals, Inc.",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100581856","phase-2-phase-2-randomized-double-blind-study-to-assess-topical-zabalafin-hydrogel-vs-vehicle-in-mild-to-moderate-ad-100581856","NCT06855745","Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.","A Phase 2, Randomized, Double-blind, Multicenter Study to Assess the Safety and Efficacy of Topical Zabalafin Hydrogel Versus Vehicle in the Treatment of Participants With Mild to Moderate Atopic Dermatitis (CLEAR-AD1)","CLEAR-AD1","Inclusion Criteria:\n\n1. Male\u002Ffemale participants who are ≥2 years of age on the day of providing documented informed consent\u002Fassent.\n2. Have a clinical diagnosis of Atopic Dermatitis (AD) according to the criteria of Hanifin and Rajka (1980) at the Screening visit and a history of AD for at least 6 months (3 months for children under the age of 6).\n3. Mild to moderate AD indicated by vIGA (Validated Investigator's Global Assessment) score of 2 (mild) or 3 (moderate) at Screening and at Day 1 prior to application of study intervention.\n4. Have AD on the head (including face, but excluding hair-bearing scalp), neck, trunk (excluding groin and genitals), or limbs, covering at least ≥2% of total BSA (body surface area) and not more than 20% at Screening and at Day 1 (Visit 1).\n5. Participants who have at least 1 lesion that measures approximately 5 cm2 or more at Screening and Day 1. Lesion must be representative of the participant's atopic dermatitis and not be located on the hands, feet, or genitalia.\n6. Have an Eczema Area and Severity Index (EASI) total score of ≥3 to ≤21 at Screening and at Day 1.\n7. Have a peak pruritus Numeric Rating Scale (NRS) score of at least 4 at Screening and at Day 1.\n8. All allowed oral and topical medications (Protocol Section 6.5) must be stable regimens within the 14 days prior to Day 1.\n9. Willing to refrain from using any topical products, including cosmetics and skin cleansers on the AD lesions during the study intervention application period (Section 6.5.1).\n10. Participants who are willing and able to comply with all study procedures, including scheduled visits, proper administration of study intervention application, lifestyle considerations.\n11. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n    * Not a woman of childbearing potential (WOCBP) OR\n    * A WOCBP who agrees to follow the contraceptive guidance in Section 10.4. Male participants are eligible to participate if they agree to follow the contraceptive guidance\n\nExclusion Criteria:\n\n1. Unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to Day 1.\n2. Concurrent conditions and history of other diseases:\n\n   1. Any other concomitant skin disorder, pigmentation, or extensive scarring that, in the opinion of the investigator, may interfere with the evaluation of AD lesions or compromise participant safety.\n   2. The presence of AD lesions only on the hands or feet without prior history of involvement of other classical areas of involvement such as the face or the folds.\n   3. Other types of atopic dermatitis.\n3. Has recent or anticipated concomitant use of systemic or topical therapies that might alter the course of AD in the opinion of the investigator\n4. Ultraviolet (UV) light therapy or prolonged exposure to artificial sources of UV radiation within 2 weeks prior to Screening and\u002For intention to have such exposure during the study.\n5. Use of any of the following treatments within the indicated washout period before Day\n\n   1. 5 half-lives or 12 weeks, whichever is longer - biologic agents (e.g. dupilumab).\n   2. 4 weeks - systemic corticosteroids or adrenocorticotropic hormone analogs, cyclosporin, methotrexate, azathioprine, or other systemic immunosuppressive or immunomodulating agents (e.g. mycophenolate or tacrolimus).\n   3. Two weeks - systemic antibiotics.\n   4. One week - use of other topical treatments for AD (other than bland emollients).\n   5. One week - topical antiviral agents, topical antibacterial agents, topical antifungal agents, topical corticosteroid agents.\n   6. One week - oral antibiotics\n6. Has undergone treatment within 5 years for any cancer except non-melanoma skin cancers, squamous cell carcinoma, basal cell carcinoma. Participants with adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ are allowed.\n7. Active or potentially recurrent dermatologic condition other than AD that may confound evaluation in the opinion of the investigator.\n8. Current or recent history (within 3 months) of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease.\n9. Have had a systemic infection within the past 3 months requiring hospitalization.\n10. Have required the use of parenteral antimicrobial, antivirals, antiprotozoals, antifungals, janus kinase inhibitors (JAK), tyrosine kinase inhibitors (TYK2, or phosphodiesterase 4 (PDE4) inhibitors, monoclonal antibodies (mABs), or other parenteral therapies as judged to be clinically significant by the Investigator within the past 3 months.\n11. Has undergone significant trauma or major surgery within 3 months prior to screening or has major surgery planned during the study.\n12. Known hypersensitivity to zabalafin or any component of the hydrogel vehicle.\n13. Has a presence of depression per the Depression and Anxiety Disorder Score (DASS) scale that is not controlled with medication or is in remission, or the presence of severe depression or suicidal ideation or behavior. Participants with severe depression\u002Fsuicidal ideation\u002Fbehavior should be referred to appropriate medical professionals for evaluation.\n14. A WOCBP who has a positive serum pregnancy test within 24 hours prior to randomization or treatment allocation.\n\n    Note: If 24 hours have elapsed between the screening pregnancy test and the first dose of study intervention, another serum pregnancy test must be performed and must be negative for participant to start receiving study intervention.\n15. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Administration of killed vaccine and mRNA vaccines are allowed.\n\n    Note: Any licensed COVID-19 vaccine (including for Emergency Use) is allowed in the study if they are Messenger Ribonucleic Acid (mRNA) vaccines, replication-incompetent adenoviral vaccines, or inactivated vaccines. These vaccines will be treated just as any other concomitant therapy. Investigational vaccines (ie, those not licensed or approved for Emergency Use) are not allowed.\n\n    Prior\u002FConcurrent Clinical Study Experience:\n16. Current treatment or treatment within 90 days or 5 half-lives (whichever is longer) before Day 1 with another investigational medication or current enrollment in another investigational drug protocol.\n\n    Other Exclusion Criteria:\n17. Investigator site staff members directly involved in the conduct of the study and their family members; site staff members otherwise supervised by the investigator, are not eligible.\n18. Has a history of alcohol or substance abuse within 6 months prior to Screening that in the opinion of the investigator will preclude participation in the study.\n19. Have any medical or psychiatric condition which, in the opinion of the Investigator or the Sponsor's Medical Monitor, would place the participant at risk, interfere with participation in the study, or interfere with the interpretation of study results.","2 Years",{"count":105,"type":21},72,[24],"A Phase 2b study investigating the efficacy of zabalafin in people with mild to moderate atopic dermatitis (eczema).",[109,84,27,110,32,34],"Atopic Dermatitis (Eczema)","Atopic Dermatitis (AD)",[32,112,113,114,29,115],"Childhood eczema","Adult eczema","AD","Infected dermatitis","2025-07-30",{"date":118,"type":39},"2025-08-01",{"date":120,"type":39},"2025-03-25",{"date":122,"type":21},"2025-11-28",{"name":124,"class":46},"Alphyn Biologics",12,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100483503","anti-relapse-efficacy-and-tolerance-assessment-of-a-cosmetic-cream-for-very-dry-irritated-to-atopic-sensitive-skin-100483503","NCT05575882","Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive Skin.","Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream Intended for Very Dry, Irritated to Atopic Sensitive Skin","Inclusion Criteria:\n\n* General criteria:\n\nHealthy subject (except AD and other atopic diseases - allergic rhinitis, conjunctivitis, and asthma). The subject can keep its usual treatment (antihistamines, inhaled corticosteroids, and antileukotriene treatment) during the study if applicable. Written informed consent from the subject's parent(s)\u002Flegal representative(s) and children over 8 years old (specific Argentina) and over 12 years old (specific Singapore). Subject accepting to continue the normal conditions of hygiene and sunscreen (if applicable). Subject, parents\u002Flegal representative(s) willing to adhere to the study protocol and procedures.\n\nSpecific criteria:\n\nSex: male or female. Age: from 6 months to 15 years. Subject having on average one flare-up per month during the four months preceding the study, including the one observed on the inclusion visit D0. Subject having EASI value from 7.1 - 21 on D0 (moderate AD). Subject having one atopic eruption on the inclusion visit which the dermatologist will prescribe topical corticosteroids or calcineurin's inhibitors (pimecrolimus and\u002For tacrolimus).\n\nExclusion Criteria:\n\n* Subject presenting cutaneous pathology in the studied zone other than AD (according to the investigator's appreciation, i.e., acne, psoriasis). Subject using systemic treatment, including oral steroids and oral immunosuppressants e.g., ciclosporin during the previous weeks liable to interfere with the assessment of the cutaneous tolerance of the study product or placebo (according to the investigator's appreciation). Subject using skin-moisturizing products from inclusion (D0) other than the study product or placebo. Subject who had systemic therapy with immune-suppressive drugs and antibiotics within the last 14 days before the beginning of the study Subject having serious illness that might require regular systemic medication (e.g., insulin-dependent diabetes, cancer) or conditions that exclude a participation or might influence the study evaluation. Subject with documented allergies to the study product or placebo ingredients. Subject enrolled in another clinical study during the study period. Parent(s)\u002Flegal representative(s) considered by the investigator to be likely not compliant to the protocol.","6 Months","15 Years",{"count":136,"type":21},100,[138],"NA","Multicentric, double blind, randomized, comparative study with two parallel group: study group vs placebo group. 5 visits: inclusion visit \\[day (D) 0\\] and 4 follow-up visits (D30, D60, D90, and D120).",[27,34],"2025-03-21",{"date":120,"type":39},{"date":144,"type":39},"2022-11-03",{"date":146,"type":21},"2025-11",{"name":148,"class":46},"NAOS Argentina S.A.",3]